AMGEN INC

Amgen’s resilient biotech pipeline keeps it near a 52‑week high, even as AI‑driven tech volatility and cautious growth‑stock sentiment loom.

Amgen’s new drug Imdelltra + Imfinzi cuts death risk by 58% in extensive‑stage small cell lung cancer, boosting median survival to 37 months.

Amgen’s robust R&D pipeline and disciplined cash‑flow strategy position the company to thrive amid stagflation, AI‑driven drug discovery, and supply‑chain resilience, driving shareholder value and growth.